NCT02260674 - A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease | Biotech Hunter

Enrollment

114

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Alzheimer's Disease

Interventions

DRUG

JNJ-54861911, 10 milligram (mg)

Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.

DRUG

JNJ-54861911, 50 mg

Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.

DRUG

Placebo

Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.

Trial Locations (19)

Unknown

Ghent

Hoboken

Montpellier

Paris

Toulouse

Essen

Halle

Hamburg

Homburg

Lübeck

Tübingen

Ulm

Amsterdam

Barcelona

Madrid

Terrasa Barcelona N/A

Valencia

Mölndal

Stockholm

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY